12/17
08:02 am
crvo
CervoMed Inc. (NASDAQ: CRVO) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
12/12
07:05 am
crvo
CervoMed Inc. (NASDAQ: CRVO) was downgraded by analysts at Brookline Capital Management from a "strong-buy" rating to a "hold" rating.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) was downgraded by analysts at Brookline Capital Management from a "strong-buy" rating to a "hold" rating.
12/12
07:00 am
crvo
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/11
12:29 pm
crvo
CervoMed Inc. (NASDAQ: CRVO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $65.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $65.00 to $12.00. They now have a "buy" rating on the stock.
12/11
09:04 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "underweight" rating re-affirmed by analysts at Morgan Stanley.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) had its "underweight" rating re-affirmed by analysts at Morgan Stanley.
12/11
08:21 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
12/10
09:44 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "hold" rating re-affirmed by analysts at D. Boral Capital.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) had its "hold" rating re-affirmed by analysts at D. Boral Capital.
12/10
07:00 am
crvo
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
High
Report
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
12/7
07:33 am
crvo
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
High
Report
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/6
08:06 am
crvo
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $45.00 price target on the stock.
High
Report
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $45.00 price target on the stock.
12/5
08:01 am
crvo
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $42.00 price target on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $42.00 price target on the stock.
11/27
08:56 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
11/27
07:00 am
crvo
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Medium
Report
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
11/14
06:30 pm
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
11/13
08:00 am
crvo
CervoMed Announces Key Senior Leadership Appointments
Medium
Report
CervoMed Announces Key Senior Leadership Appointments
11/12
07:00 am
crvo
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Low
Report
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
11/8
09:55 am
crvo
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
Low
Report
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
11/7
08:30 am
crvo
CervoMed to Participate in Upcoming Investor Conferences
Medium
Report
CervoMed to Participate in Upcoming Investor Conferences
11/4
08:00 am
crvo
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
High
Report
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/29
08:00 am
crvo
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Low
Report
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
10/15
08:00 am
crvo
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
Low
Report
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
10/2
08:00 am
crvo
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Medium
Report
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
9/26
08:00 am
crvo
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
High
Report
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)